Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024

Estrella Immunopharma, Inc.

Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.
Transition period covers July 1, 2024 through December 31, 2024.
Company will file Form 10-KT with audited financials for the transition period.

item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Estrella Immunopharma, Inc.: Changed fiscal year end from June 30 to December 31 (effective 2024-11-25).

Change: fiscal year change
Effective: 2024-11-25

Exact text from the filing

On November 25, 2024, in order to align the fiscal year of Estrella Immunopharma, Inc. (the “ Company ”) with the calendar year and facilitate the Company’s accounting and reporting processes, the Board of Directors of the Company approved a change in the Company’s fiscal year end from June 30 to December 31.

View on SEC.gov

Browse all governance changes →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-102899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.